ClinicalTrials.gg
RecruitingNCT07105930OrFitAUpdated Nov 6, 2026

Trial to Assess Non-inferiority of an Orbital Atherectomy Only Versus a Calcium-tailored Debulking Approach

An interventional study of Debulging approach using the orbital atherectomy system and Debulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy in Orbital Atherectomy, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Some patients with coronary artery disease have severely calcified vessels. In these cases, placing a stent - a small tube that helps keep the artery open - can be very difficult. Calcium build-up in the artery wall may prevent the stent from expanding properly, increasing the risk of complications or failure of the treatment.

To prepare these vessels before stenting, doctors use special techniques to modify or remove the calcium. These techniques are known as plaque modification strategies and can include devices such as atherectomy systems, scoring balloons, or intravascular lithotripsy. However, there is no clear standard as to which strategy is best.

Purpose of the Study:

This study compares two different approaches to treating calcified coronary arteries before stenting:

  • A uniform approach using only the orbital atherectomy system (Diamondback 360®, Abbott), which sands away the calcium with a rotating crown
  • A tailored approach, where the operator chooses from various available methods (e.g., rotational atherectomy, scoring or cutting balloons, or shockwave therapy) based on the patient's specific type of calcium The goal is to determine whether the uniform orbital atherectomy approach is not worse (non-inferior) than the individualized method when it comes to how well the stent expands inside the artery.

This is a randomized, controlled clinical trial. Patients will be randomly assigned to one of the two groups.

Randomization ensures fair comparison between both groups. The decision to implant a stent and to use additional techniques is at the discretion of the interventional cardiologist.

02

Conditions studied

  • Orbital Atherectomy
03

In context

Lead sponsor

IHF GmbH - Institut für Herzinfarktforschung is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 Years
  • Chronic coronary syndrome with a clinical indication for percutaneous coronary intervention of a severely calcified lesion as defined by coronary computer tomography (CT; Agatston Score of target lesion ≥453 OR Calcium Arc >270°). The determination of calcification in the target lesion is based on native and contrast enhanced CT scans that are conducted as per clinical guidelines. The CT images must not be older than 6 months at the time of patient enrollment.
  • Signed
  • The patient is an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy

Exclusion criteria

Exclusion Criteria:

  • Acute ST-Elevation Acute Coronary Syndrome (STE-ACS) within 48 hours
  • Cardiogenic shock
  • Chronic total occlusion of the target lesion
  • \< 30 ml/min/1.73 m2
  • Known presence, at the time of enrollment, of any listed in the Instructions for Use (IFU) of the device:

    • The OCT (optical coherence tomography) imaging catheter cannot cross
    • The wire or imaging catheter cannot cross
    • The target lesion is within a bypass graft or stent
    • The patient is not an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy.
    • The patient has angiographic evidence of thrombus
    • The patient has only one open coronary vessel
    • The patient has angiographic evidence of flow reducing dissection at the treatment site
    • The patient has a known to egg-, soy-, or peanut protein or to any of the active substances or of the ViperSlide™ lubricant
    • Pregnancy (assessed by clinical routine testing)
  • Participation in another interventional clinical trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Debulging with the orbital atherectomy system (Diamondback 360®)

    Device: Debulging approach using the orbital atherectomy system

  • Active comparator
    Debulging with various available methods

    Procedure: Debulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy

Interventions

  • DeviceDebulging approach using the orbital atherectomy system

    A uniform approach using only the orbital atherectomy system (Diamondback 360®), which sands away the calcium with a rotating crown

  • ProcedureDebulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy

    A tailored approach, where the operator chooses from various available methods based on the patient's specific type of calcium

06

What researchers measure

Primary outcomes

  1. Post-procedural Minimal Stent Area (MSA %) as assessed by optical coherence to-mography (OCT) imaging

    Time frame: MSA will be assessed in the final OCT run performed after stent implantation withine baseline

07

Study locations

1 of 1 sites recruiting
  • Universitäres Herz - und Gefäßzentrum, Unversitätsklinikum Frankfurt
    Frankfurt, Germany
    Recruiting
    • Marco Ochs, PD Dr. med. · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 6, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07105930
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Oct 30, 2025
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Marcel Kunadt, Dr.
Contact
orfita@ihf.de
+49 621 59577 223
Jelena Weller
Contact
Marco Ochs, PD Dr.
principal investigator · Universitäres Herz- und Gefäßzentrum Frankfurt ZIM - Med. Clinic 3 - Cardiology and Angiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion